Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Pelvic Pain Associated With Refractory Endometriosis
Interventions: BGS649, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Preeclampsia, Aspirin, Clinical Decision Support Systems, Economics, Behavioral
Interventions: Electronic health record best practice alert; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: Female only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Pitolisant; Drug
Lead sponsor: High Point Clinical Trials Center; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Gulf War Illness
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: Roskamp Institute Inc.; Other
Eligibility: 47 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Sarasota, Florida

Conditions: Labor Analgesia
Interventions: Traditional ultrasound, Automated ultrasound; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Coagulation, Bleeding, Thrombosis
Interventions: Phytonadione (Vitamin K1); Drug
Lead sponsor: St. Joseph's Healthcare Hamilton; Other
Eligibility: 18 Years and older
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Westminster, Colorado • Albuquerque, New Mexico

Conditions: Primary Immune Deficiency
Interventions: GC5107; Biological
Lead sponsor: GC Biopharma Corp; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more

Conditions: Healthy
Interventions: AZD6765, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Beta-Thalassemia
Interventions: VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID, Placebo; Drug
Lead sponsor: Vifor (International) Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Whittier, California

Conditions: Substance Abuse
Interventions: Free2b, Attention-Placebo; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 15 Years to 17 Years
Enrollment: 1,216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Kidney Disease Associated Moderate to Severe Pruritus
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 47
States / cities: Bakersfield, California • Glendale, California • La Palma, California + 40 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Olanzapine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 33
States / cities: Anaheim, California • National City, California • Orange, California + 30 more

Conditions: Sciatica
Interventions: CEP-37247, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 20
States / cities: La Mesa, California • Laguna Hills, California • Pasadena, California + 15 more

Conditions: Precancerous Condition
Interventions: celecoxib, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 7
States / cities: Birmingham, Alabama • Irvine, California • Ann Arbor, Michigan + 4 more

Conditions: Schizophrenia
Interventions: PF-05180999, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Type 2
Interventions: linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • Spring Valley, California • Walnut Creek, California + 16 more

Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Acupressure Therapy, Best Practice, Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions: rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 86
States / cities: Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more

Conditions: Congenital Hyperinsulinism
Interventions: RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC; Drug
Lead sponsor: Rezolute; Other
Eligibility: 3 Months to 45 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Fort Worth, Texas

Conditions: Diabetic Foot, Chronic Foot Ulcer, Wound Healing, Foot Ulcer
Interventions: SynPath Acellular Dermal Matrix plus Off-loading Device, Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device; Device
Lead sponsor: PolyNovo Biomaterials Pty Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Castro Valley, California • Fresno, California • Vista, California + 4 more

Conditions: Schizophrenia
Interventions: Sildenafil; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Posttraumatic Stress Disorder (PTSD), Substance Use Disorder (SUD)
Interventions: Written Exposure Therapy, Treatment as Usual; Behavioral
Lead sponsor: Potomac Health Foundations; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depression, Depression, Postpartum
Interventions: Omega-3 Fatty Acids (EPA plus DHA), Supportive psychotherapy, Placebo; Drug · Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Candida Vulvovaginitis
Interventions: Ibrexafungerp, Placebo; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more

Search by objective public record fields.

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Low Dose Aspirin Alerts in High-Risk Pregnancies

Insulin Tolerance Test Study in Patients With Type 1 Diabetes

Nicotinamide Riboside Clinical Trial for GWI

The Impact of Needle Manipulation and Accuracy Between Hand Held Automatic and Traditional Ultrasound Device

Oral Vitamin K for Warfarin Associated Coagulopathy

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Preventing Drug Abuse Among Sexual Minority Youth

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

RZ358 Treatment for Congenital Hyperinsulinism

Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers

A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia

Written Exposure in Substance Treatment (WEST 3.0): Randomized Controlled Trial

Use of Omega-3 Fatty Acids for Perinatal Depression

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)